We are live on ! Find out more
TOVX icon

Theriva Biologics
TOVX

17 hedge funds and large institutions have $725K invested in Theriva Biologics in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

51% more capital invested

Capital invested by funds: $479K → $725K (+$246K)

0% less ownership

Funds ownership: 0.27% → 0.26% (-0%)

15% less funds holding

Funds holding: 20 → 17 (-3)

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

Holders
17
Holders Change
-3
Holders Change %
-15%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
–
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$17.1K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$8.86K
3
Renaissance Technologies
Renaissance Technologies
New York
+$1.82K

Top Sellers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
-$13K
2
Two Sigma Advisers
Two Sigma Advisers
New York
-$5.45K
3
UBS Group
UBS Group
Switzerland
-$2.31K
4
Morgan Stanley
Morgan Stanley
New York
-$560
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$4
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$367K – – –
BlackRock
2
BlackRock
New York
$133K – – –
Geode Capital Management
3
Geode Capital Management
Massachusetts
$81.2K – – –
State Street
4
State Street
Massachusetts
$34K – – –
Northern Trust
5
Northern Trust
Illinois
$24.9K – – –
Renaissance Technologies
6
Renaissance Technologies
New York
$24K +$1.82K +88 +7%
BCM
7
Bridgeway Capital Management
Texas
$19.9K – – –
Citadel Advisors
8
Citadel Advisors
Florida
$14.4K +$17.1K +824 New
Charles Schwab
9
Charles Schwab
California
$9.47K – – –
Fisher Asset Management
10
Fisher Asset Management
Washington
$8.78K – – –
Susquehanna International Group
11
Susquehanna International Group
Pennsylvania
$7.46K +$8.86K +427 New
IA
12
IFP Advisors
Florida
$572 – – –
Wells Fargo
13
Wells Fargo
California
$77 – – –
Osaic Holdings
14
Osaic Holdings
Arizona
$32 – – –
Bank of America
15
Bank of America
North Carolina
$14 – – –
SPIA
16
Steward Partners Investment Advisory
New York
$10 – – –
Morgan Stanley
17
Morgan Stanley
New York
$7 -$560 -27 Closed
VF
18
Virtu Financial
New York
– -$13K -1,159 Closed
Two Sigma Advisers
19
Two Sigma Advisers
New York
– -$5.45K -480 Closed
UBS Group
20
UBS Group
Switzerland
– -$2.31K -201 Closed
Fidelity Investments
21
Fidelity Investments
Massachusetts
– -$4 – –

TOVX Hedge Fund Activity: Q1 2023 in Review

17 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q1 2023, worth a combined $725K — up 51% from $479K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of TOVX and 2 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $17.1K. The largest seller was Virtu Financial, exiting entirely with an estimated $13K sold.

  • 17 institutional investors held Theriva Biologics (TOVX) as of Q1 2023, down from 20 in Q4 2022.
  • Funds reported $725K of Theriva Biologics stock for Q1 2023, up 51% quarter-over-quarter.
  • 2 funds opened new Theriva Biologics positions in Q1 2023 and 5 closed out, a net change of -3 holders.
  • The largest Theriva Biologics buyer in Q1 2023 was Citadel Advisors, an estimated $17.1K added.
  • The largest Theriva Biologics seller in Q1 2023 was Virtu Financial, an estimated $13K sold.

Based on aggregated 13F filings for Q1 2023.